Julie Hill
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Psoriasis: Treatment and Pathogenesis, Systemic Lupus Erythematosus Research, Spondyloarthritis Studies and Treatments, Diabetes Treatment and Management
Most-Cited Works
- → EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial(2014)195 cited
- → A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis(2006)179 cited
- → Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study(2017)108 cited
- → Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin(2019)50 cited
- → Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*(2012)41 cited
- → Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)(2022)38 cited
- College Student Perceptions and Ideals of Teaching: An Exploratory Pilot Study(2012)
- → The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice(2017)7 cited
- → North Carolina Sexual Offender Legislation: Policy Placebo?(2012)2 cited
- A retrospective chart review of mabthera (rituximab) for rheumatoid arthritis (Ra) in Australian rheumatology practice(2012)